液体活检是一种微创方法，用于检测体液（特别是血液）中的生物标志物，在肿瘤学中的临床应用越来越多。由于 DNA 分析技术的改进，首先是新一代测序 (NGS) 检测，循环肿瘤 DNA (ctDNA) 已成为大多数类型癌症（包括非小细胞）最有信息的肿瘤来源材料。肺癌（NSCLC）。尽管晚期肿瘤患者的 ctDNA 浓度较高，但即使在早期疾病患者中也可以检测到。因此，ctDNA在早期肺癌治疗中的大量临床应用不断涌现，例如肺癌筛查、微小残留病（MRD）的识别以及放射学进展前的复发预测。此外，大量临床试验正在进行中，以更好地确定 ctDNA 评估在此情况下的影响。本次综述的目的是全面概述使用 ctDNA 管理早期肺癌的最相关实施，解决现有数据、技术方面、局限性和未来前景。版权所有 © 2024 作者。由爱思唯尔有限公司出版。保留所有权利。

Liquid biopsy is a minimally invasive method for biomarkers detection in body fluids, particularly in blood, which offers an elevated and growing number of clinical applications in oncology. As a result of the improvement in the techniques for DNA analysis, above all next-generation sequencing (NGS) assays, circulating tumor DNA (ctDNA) has become the most informing tumor-derived material for most types of cancer, including non-small cell lung cancer (NSCLC). Although ctDNA concentration is higher in patients with advanced tumors, it can be detected even in patients with early-stage disease. Therefore, numerous clinical applications of ctDNA in the management of early-stage lung cancer are emerging, such as lung cancer screening, the identification of minimal residual disease (MRD), and the prediction of relapse before radiologic progression. Moreover, a high number of clinical trials are ongoing to better define the impact of ctDNA evaluation in this setting. Aim of this review is to offer a comprehensive overview of the most relevant implementations in using ctDNA for the management of early-stage lung cancer, addressing available data, technical aspects, limitations, and future perspectives.Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.